Expert Interviews

Radiation oncologist Kamran Ahmed, MD, comments on indications for using radiation therapy to treat patients with HER2-positive de novo metastatic breast cancer.

The rationale for treating Erika Rich, a patient with HER2-positive metastatic breast cancer, with docetaxel, trastuzumab, and pertuzumab.

Axel Merseburger, MD, PhD, spoke key results of the PRESIDE trial, which examined continuous enzalutamide to treat patients with metastatic castration-resistant prostate cancer and progressive disease.

Two experts discuss cytogenetic profiles in patients with relapsed/refractory multiple myeloma treated with either doublet or triplet therapy.

Hope S. Rugo, MD, MBA, and Paolo Tarantino, MD, give a preview to a first-of-its-kind Tweet Chat taking place in January 2023.

Chung-Han Lee, MD, PhD, spoke about using biomarkers to help predict responses in patients with metastatic renal cell carcinoma treated on the KEYNOTE-146 study.

Eleni Efstathiou, MD, PhD, spoke about the treatment combination of niraparib plus abiraterone acetate and prednisone for the treatmeant of men with metastatic castration-resistant prostate cancer in the phase 3 MAGNITUDE trial.

Hematologic oncologists summarize the dose ranging study of ponatinib in patients with CML and discuss clinical implications of this work.

Jorge E. Cortes, MD, presents data from a dose ranging study of ponatinib in patients with chronic-phase chronic myeloid leukemia.

Patient advocate Erika Rich compares initial symptoms that prompted her to seek a medical evaluation with symptoms commonly associated with HER2-positive metastatic breast cancer.

A discussion regarding treatment advances in HER2-positive metastatic breast cancer, a heterogeneous disease.

Data review of IRD vs Rd in patients with relapsed/refractory multiple myeloma who had a prior autologous stem cell transplant or extramedullary disease.

An overview of what’s next, in terms of the use of various frontline treatment regimens, that include novel agents to manage patients with newly diagnosed multiple myeloma.

Recommendations regarding best approaches to using novel therapies to treat multiple myeloma based on current drug approvals as well as new therapies in the pipeline.

Treatment options available for an elderly man with multiple myeloma upon first relapse.

Advice for community physicians treating HER2+ breast cancer.

Ghassan K. Abou-Alfa, MD, examined the trial design of the phase 3 HIMALAYA trial of tremelimumab plus durvalumab for frontline hepatocellular carcinoma, with results presented at the 2022 Gastrointestinal Cancers Symposium.

Amitkumar Mehta, MD, detailed encouraging data presented at the 63rd ASH Annual Meeting for treating mantle cell lymphoma.

Michael R. Bishop, MD, discussed how he thinks the results from phase 3 BELINDA study may impact the treatment landscape in B-cell lymphomas moving forward.

Experts provide commentary on the subgroup analyses from real-world data on use of ixazomib, lenalidomide, and dexamethasone compared with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.